Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics (NASDAQ: RPRX) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.
Repros facts
|
|
Headquarters (founded) |
The Woodlands, Texas (1987) |
Market Cap |
$370.6 million |
Industry |
Pharmaceuticals |
Trailing-12-Month EBITDA |
($22.9 million) |
Management |
CEO Joseph Podolski (since 1992) CFO Katherine Anderson (since 2011) |
Return on Capital (average, past 3 years) |
(72.6%) |
Cash/Debt |
$17.2 million/$0 |
Competitors |
Abbott Labs Actavis Auxilium Pharmaceuticals |
On CAPS, 52% of the 132 members who have rated Repros believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bear case for our community:
A year ago I did some in depth research on Repros and concluded that at a share price of [$9.00] the stock was untouchable. I couldn't impeach their science but the company had a long-standing pedigree of misrepresentation dating back to their days as Zonagen. ...
I stood on the sidelines and today the stock stands at double where it was when I drew my prior conclusions. This comes despite a couple of notable setbacks: a data issue in the ZA-301 trial of Androxal that might be grounds for an eventual CRL, and the FDA refusal to permit the company to move directly to a phase III trial of vaginal Proellex for uterine fibroids. I think Repros has benefited from the recent forgiving mood of the market toward the biotech sector in general, but all pendulums eventually swing. A market cap of [$370M] doesn't seem like a lot compared to some other frothy companies, but I'll make a measured bet that Repros has gotten a little ahead of itself.